Abstract
Imbalances in redox homeostasis have been described to be involved in the development, progression and relapse of leukemia. As the thioredoxin (Trx) system, one of the major cellular antioxidant networks, has been implicated in acute lymphoblastic leukemia (ALL), we investigated the therapeutic potential of Trx inhibition in ALL. Here, we show that the Trx inhibitor PX-12 reduced cell viability and induced cell death in a dose- and time-dependent manner in different ALL cell lines. This antileukemic activity was accompanied by an increase in reactive oxygen species (ROS) levels and enhanced PRDX3 dimerization. Pre-treatment with the thiol-containing ROS scavenger N-acetylcysteine (NAC), but not with non-thiol-containing scavengers α-tocopherol (α-Toc) or Mn(III)tetrakis(4-benzoic acid) porphyrin chloride (MnTBAP), significantly rescued PX-12-induced cell death. Furthermore, PX-12 triggered activation of BAK. Importantly, knockdown of BAK reduced PX-12-stimulated ROS production and cell death. Similarly, silencing of NOXA provided significant protection from PX-12-mediated cell death. The relevance of mitochondria-mediated, caspase-dependent apoptosis was further supported by data showing that PX-12 triggered cleavage of caspase-3 and that addition of the broad-range caspase inhibitor carbobenzoxy-valyl-alanyl-aspartyl-[O-methyl]-fluoromethylketone (zVAD.fmk) potently blocked cell death upon PX-12 treatment. This study provides novel insights into the mechanisms of PX-12-induced cell death in ALL and further highlights the therapeutic potential of redox-active compounds in ALL.
Acknowledgments
We thank C. Hugenberg for expert secretarial assistance. This work has been partially supported by grants from the DFG, Funder Id: http://dx.doi.org/10.13039/501100001659, Grant Number: SFB 815 (to S.F.) and BMBF (to S.F.).
Conflict of interest statement: None declared.
References
Adams, J.M. and Cory, S. (2007). Bcl-2-regulated apoptosis: mechanism and therapeutic potential. Curr. Opin. Immunol. 19, 488–496.10.1016/j.coi.2007.05.004Search in Google Scholar PubMed PubMed Central
Albert, A., Brauckmann, C., Blaske, F., Sperling, M., Engelhard, C., and Karst, U. (2012). Speciation analysis of the antirheumatic agent Auranofin and its thiol adducts by LC/ESI-MS and LC/ICP-MS. J. Anal. Atom. Spectrom. 27, 975–981.10.1039/c2ja30109aSearch in Google Scholar
Albert, M.C., Brinkmann, K., and Kashkar, H. (2014). Noxa and cancer therapy: Tuning up the mitochondrial death machinery in response to chemotherapy. Mol. Cell. Oncol. 1, e29906.10.4161/mco.29906Search in Google Scholar PubMed PubMed Central
Arner, E.S. (2009). Focus on mammalian thioredoxin reductases – important selenoproteins with versatile functions. Biochim. Biophys. Acta 1790, 495–526.10.1016/j.bbagen.2009.01.014Search in Google Scholar PubMed
Baker, A.F., Adab, K.N., Raghunand, N., Chow, H., Stratton, S.P., Squire, S.W., Boice, M., Pestano, L.A., Kirkpatrick, D.L., and Dragovich, T. (2013). A phase IB trial of 24-hour intravenous PX-12, a thioredoxin-1 inhibitor, in patients with advanced gastrointestinal cancers. Invest. New Drugs 31, 631–641.10.1007/s10637-012-9846-2Search in Google Scholar PubMed PubMed Central
Chen, Y.F., Liu, H., Luo, X.J., Zhao, Z., Zou, Z.Y., Li, J., Lin, X.J., and Liang, Y. (2017). The roles of reactive oxygen species (ROS) and autophagy in the survival and death of leukemia cells. Crit. Rev. Oncol. Hematol. 112, 21–30.10.1016/j.critrevonc.2017.02.004Search in Google Scholar PubMed
Circu, M.L. and Aw, T.Y. (2010). Reactive oxygen species, cellular redox systems, and apoptosis. Free Radic. Biol. Med. 48, 749–762.10.1016/j.freeradbiomed.2009.12.022Search in Google Scholar PubMed PubMed Central
Cory, S. and Adams, J.M. (2002). The Bcl2 family: regulators of the cellular life-or-death switch. Nat. Rev. Cancer 2, 647–656.10.1038/nrc883Search in Google Scholar PubMed
Fulda, S. (2009). Tumor resistance to apoptosis. Int. J. Cancer 124, 511–515.10.1002/ijc.24064Search in Google Scholar PubMed
Fulda, S., Sieverts, H., Friesen, C., Herr, I., and Debatin, K.M. (1997). The CD95 (APO-1/Fas) system mediates drug-induced apoptosis in neuroblastoma cells. Cancer Res. 57, 3823–3829.Search in Google Scholar
Gorrini, C., Harris, I.S., and Mak, T.W. (2013). Modulation of oxidative stress as an anticancer strategy. Nat. Rev. Drug Discov. 12, 931–947.10.1038/nrd4002Search in Google Scholar PubMed
Haas, B., Schutte, L., Wos-Maganga, M., Weickhardt, S., Timmer, M., and Eckstein, N. (2018). Thioredoxin confers intrinsic resistance to cytostatic drugs in human glioma cells. Int. J. Mol. Sci. 19, 2874.10.3390/ijms19102874Search in Google Scholar
Hass, C., Belz, K., Schoeneberger, H., and Fulda, S. (2016). Sensitization of acute lymphoblastic leukemia cells for LCL161-induced cell death by targeting redox homeostasis. Biochem. Pharmacol. 105, 14–22.10.1016/j.bcp.2016.01.004Search in Google Scholar
Habermann, K.J., Grunewald, L., van Wijk, S., and Fulda, S. (2017). Targeting redox homeostasis in rhabdomyosarcoma cells: GSH-depleting agents enhance auranofin-induced cell death. Cell Death Dis. 8, e3067.10.1038/cddis.2017.412Search in Google Scholar
Hansen, J.M., Zhang, H., and Jones, D.P. (2006). Mitochondrial thioredoxin-2 has a key role in determining tumor necrosis factor-αl-induced reactive oxygen species generation, NF-kappaB activation, and apoptosis. Toxicol. Sci. 91, 643–650.10.1093/toxsci/kfj175Search in Google Scholar
Inaba, H., Greaves, M., and Mullighan, C.G. (2013). Acute lymphoblastic leukaemia. Lancet 381, 1943–1955.10.1016/S0140-6736(12)62187-4Search in Google Scholar
Irwin, M.E., Rivera-Del Valle, N., and Chandra, J. (2013). Redox control of leukemia: from molecular mechanisms to therapeutic opportunities. Antioxid. Redox. Signal. 18, 1349–1383.10.1089/ars.2011.4258Search in Google Scholar
Juo, P., Woo, M.S., Kuo, C.J., Signorelli, P., Biemann, H.P., Hannun, Y.A., and Blenis, J. (1999). FADD is required for multiple signaling events downstream of the receptor Fas. Cell Growth Differ. 10, 797–804.Search in Google Scholar
Kekulandara, D.N., Nagi, S., Seo, H., Chow, C.S., and Ahn, Y.H. (2018). Redox-inactive peptide disrupting Trx1-Ask1 interaction for selective activation of stress signaling. Biochemistry 57, 772–780.10.1021/acs.biochem.7b01083Search in Google Scholar
Kirkpatrick, D.L., Kuperus, M., Dowdeswell, M., Potier, N., Donald, L.J., Kunkel, M., Berggren, M., Angulo, M., and Powis, G. (1998). Mechanisms of inhibition of the thioredoxin growth factor system by antitumor 2-imidazolyl disulfides. Biochem. Pharmacol. 55, 987–994.10.1016/S0006-2952(97)00597-2Search in Google Scholar
Li, G.Z., Liang, H.F., Liao, B., Zhang, L., Ni, Y.A., Zhou, H.H., Zhang, E.L., Zhang, B.X., and Chen, X.P. (2015). PX-12 inhibits the growth of hepatocelluar carcinoma by inducing S-phase arrest, ROS-dependent apoptosis and enhances 5-FU cytotoxicity. Am. J. Transl. Res. 7, 1528–1540.Search in Google Scholar
Li, G., Gao, K., Chi, Y., Zhang, X., Mitsui, T., Yao, J., and Takeda, M. (2016). Upregulation of connexin43 contributes to PX-12-induced oxidative cell death. Tumour Biol. 37, 7535–7546.10.1007/s13277-015-4620-7Search in Google Scholar PubMed
May, H.C., Yu, J.J., Guentzel, M.N., Chambers, J.P., Cap, A.P., and Arulanandam, B.P. (2018). Repurposing Auranofin, Ebselen, and PX-12 as antimicrobial agents targeting the thioredoxin system. Front Microbiol. 9, 336.10.3389/fmicb.2018.00336Search in Google Scholar PubMed PubMed Central
Metcalfe, C., Ramasubramoni, A., Pula, G., Harper, M.T., Mundell, S.J., and Coxon, C.H. (2016). Thioredoxin inhibitors attenuate platelet function and thrombus formation. PLoS One 11, e0163006.10.1371/journal.pone.0163006Search in Google Scholar
Nishinaka, Y., Nishiyama, A., Masutani, H., Oka, S., Ahsan, K.M., Nakayama, Y., Ishii, Y., Nakamura, H., Maeda, M., and Yodoi, J. (2004). Loss of thioredoxin-binding protein-2/vitamin D3 up-regulated protein 1 in human T-cell leukemia virus type I-dependent T-cell transformation: implications for adult T-cell leukemia leukemogenesis. Cancer Res. 64, 1287–1292.10.1158/0008-5472.CAN-03-0908Search in Google Scholar
Nonn, L., Williams, R.R., Erickson, R.P., and Powis, G. (2003). The absence of mitochondrial thioredoxin 2 causes massive apoptosis, exencephaly, and early embryonic lethality in homozygous mice. Mol. Cell Biol. 23, 916–922.10.1128/MCB.23.3.916-922.2003Search in Google Scholar
Peskin, A.V., Dickerhof, N., Poynton, R.A., Paton, L.N., Pace, P.E., Hampton, M.B., and Winterbourn, C.C. (2013). Hyperoxidation of peroxiredoxins 2 and 3: rate constants for the reactions of the sulfenic acid of the peroxidatic cysteine. J. Biol. Chem. 288, 14170–14177.10.1074/jbc.M113.460881Search in Google Scholar
Pui, C.H., Robison, L.L., and Look, A.T. (2008). Acute lymphoblastic leukaemia. Lancet 371, 1030–1043.10.1016/S0140-6736(08)60457-2Search in Google Scholar
Ramanathan, R.K., Kirkpatrick, D.L., Belani, C.P., Friedland, D., Green, S.B., Chow, H.H., Cordova, C.A., Stratton, S.P., Sharlow, E.R., Baker, A., et al. (2007). A Phase I pharmacokinetic and pharmacodynamic study of PX-12, a novel inhibitor of thioredoxin-1, in patients with advanced solid tumors. Clin. Cancer Res. 13, 2109–2114.10.1158/1078-0432.CCR-06-2250Search in Google Scholar PubMed
Ramanathan, R.K., Abbruzzese, J., Dragovich, T., Kirkpatrick, L., Guillen, J.M., Baker, A.F., Pestano, L.A., Green, S., and Von Hoff, D.D. (2011). A randomized phase II study of PX-12, an inhibitor of thioredoxin in patients with advanced cancer of the pancreas following progression after a gemcitabine-containing combination. Cancer Chemother. Pharmacol. 67, 503–509.10.1007/s00280-010-1343-8Search in Google Scholar PubMed
Ramanathan, R.K., Stephenson, J.J., Weiss, G.J., Pestano, L.A., Lowe, A., Hiscox, A., Leos, R.A., Martin, J.C., Kirkpatrick, L., and Richards, D.A. (2012). A phase I trial of PX-12, a small-molecule inhibitor of thioredoxin-1, administered as a 72-hour infusion every 21 days in patients with advanced cancers refractory to standard therapy. Invest. New Drugs 30, 1591–1596.10.1007/s10637-011-9739-9Search in Google Scholar PubMed
Raninga, P.V., Di Trapani, G., Vuckovic, S., Bhatia, M., and Tonissen, K.F. (2015). Inhibition of thioredoxin 1 leads to apoptosis in drug-resistant multiple myeloma. Oncotarget 6, 15410–15424.10.18632/oncotarget.3795Search in Google Scholar PubMed PubMed Central
Rohde, K., Kleinesudeik, L., Roesler, S., Lowe, O., Heidler, J., Schroder, K., Wittig, I., Drose, S., and Fulda, S. (2017). A Bak-dependent mitochondrial amplification step contributes to Smac mimetic/glucocorticoid-induced necroptosis. Cell Death Differ. 24, 83–97.10.1038/cdd.2016.102Search in Google Scholar PubMed PubMed Central
Salzer, W.L., Devidas, M., Carroll, W.L., Winick, N., Pullen, J., Hunger, S.P., and Camitta, B.A. (2010). Long-term results of the pediatric oncology group studies for childhood acute lymphoblastic leukemia 1984–2001: a report from the children’s oncology group. Leukemia 24, 355–370.10.1038/leu.2009.261Search in Google Scholar PubMed PubMed Central
Samaranayake, G.J., Troccoli, C.I., Huynh, M., Lyles, R.D.Z., Kage, K., Win, A., Lakshmanan, V., Kwon, D., Ban, Y., Chen, S.X., et al. (2017). Thioredoxin-1 protects against androgen receptor-induced redox vulnerability in castration-resistant prostate cancer. Nat. Commun. 8, 1204.10.1038/s41467-017-01269-xSearch in Google Scholar PubMed PubMed Central
Shao, L., Diccianni, M.B., Tanaka, T., Gribi, R., Yu, A.L., Pullen, J.D., Camitta, B.M., and Yu, J. (2001). Thioredoxin expression in primary T-cell acute lymphoblastic leukemia and its therapeutic implication. Cancer Res. 61, 7333–7338.Search in Google Scholar
Shin, H.R., You, B.R., and Park, W.H. (2013). PX-12-induced HeLa cell death is associated with oxidative stress and GSH depletion. Oncol. Lett. 6, 1804–1810.10.3892/ol.2013.1637Search in Google Scholar PubMed PubMed Central
Sobotta, M.C., Liou, W., Stocker, S., Talwar, D., Oehler, M., Ruppert, T., Scharf, A.N., and Dick, T.P. (2015). Peroxiredoxin-2 and STAT3 form a redox relay for H2O2 signaling. Nat. Chem. Biol. 11, 64–70.10.1038/nchembio.1695Search in Google Scholar PubMed
Spyrou, G., Enmark, E., Miranda-Vizuete, A., and Gustafsson, J. (1997). Cloning and expression of a novel mammalian thioredoxin. J. Biol. Chem. 272, 2936–2941.10.1074/jbc.272.5.2936Search in Google Scholar PubMed
Stocker, S., Van Laer, K., Mijuskovic, A., and Dick, T.P. (2018). The conundrum of hydrogen peroxide signaling and the emerging role of peroxiredoxins as redox relay hubs. Antioxid. Redox Signal 28, 558–573.10.1089/ars.2017.7162Search in Google Scholar PubMed
Tan, Y., Bi, L., Zhang, P., Wang, F., Lin, F., Ni, W., Wu, J., and Jiang, L. (2014). Thioredoxin-1 inhibitor PX-12 induces human acute myeloid leukemia cell apoptosis and enhances the sensitivity of cells to arsenic trioxide. Int. J. Clin. Exp. Pathol. 7, 4765–4773.Search in Google Scholar
Tanaka, T., Hosoi, F., Yamaguchi-Iwai, Y., Nakamura, H., Masutani, H., Ueda, S., Nishiyama, A., Takeda, S., Wada, H., Spyrou, G., et al. (2002). Thioredoxin-2 (TRX-2) is an essential gene regulating mitochondria-dependent apoptosis. EMBO J. 21, 1695–1703.10.1093/emboj/21.7.1695Search in Google Scholar PubMed PubMed Central
Tourneur, L. and Chiocchia, G. (2010). FADD: a regulator of life and death. Trends Immunol. 31, 260–269.10.1016/j.it.2010.05.005Search in Google Scholar PubMed
Wang, F., Lin, F., Zhang, P., Ni, W., Bi, L., Wu, J., and Jiang, L. (2015). Thioredoxin-1 inhibitor, 1-methylpropyl 2-imidazolyl disulfide, inhibits the growth, migration and invasion of colorectal cancer cell lines. Oncol. Rep. 33, 967–973.10.3892/or.2014.3652Search in Google Scholar PubMed
Wonsey, D.R., Zeller, K.I., and Dang, C.V. (2002). The c-Myc target gene PRDX3 is required for mitochondrial homeostasis and neoplastic transformation. Proc. Natl. Acad. Sci. U.S.A. 99, 6649–6654.10.1073/pnas.102523299Search in Google Scholar PubMed PubMed Central
You, B.R., Shin, H.R., and Park, W.H. (2014). PX-12 inhibits the growth of A549 lung cancer cells via G2/M phase arrest and ROS-dependent apoptosis. Int. J. Oncol. 44, 301–308.10.3892/ijo.2013.2152Search in Google Scholar PubMed
Zheng, Z., Fan, S., Zheng, J., Huang, W., Gasparetto, C., Chao, N.J., Hu, J., and Kang, Y. (2018). Inhibition of thioredoxin activates mitophagy and overcomes adaptive bortezomib resistance in multiple myeloma. J. Hematol. Oncol. 11, 29.10.1186/s13045-018-0575-7Search in Google Scholar PubMed PubMed Central
©2020 Walter de Gruyter GmbH, Berlin/Boston
